查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1517555

肿瘤营养市场 - 按癌症类型（食道、肝癌、胰臟、胃）、产品类型（蛋白质、维生素、矿物质）、配方（标准、元素）、给药途径、剂量类型（液体、粉末）、最终用途 - 2024 - 2032 年全球预测

Oncology Nutrition Market - By Cancer Type (Esophageal, Liver, Pancreatic, Stomach), Product Type (Protein, Vitamin, Mineral), Formulation (Standard, Elemental), Route of Administration, Dosage Type (Liquid, Powder), End-use- Global Forecast 2024 - 2032
出版日期: | 出版商: Global Market Insights Inc. | 英文 140 Pages | 商品交期: 2-3个工作天内

价格
简介目录

随着人们对营养在癌症治疗中至关重要作用的认识不断增强，以及医学研究的进步，肿瘤营养市场规模从 2024 年到 2032 年将达到 8.1% 的复合年增长率。随着医疗保健提供者和患者认识到客製化营养支持在管理治疗副作用和改善结果方面的好处，对专门肿瘤营养产品的需求正在上升。正在进行的研究继续完善营养策略，强调其对患者康復和生活品质的影响。这些因素共同推动了该领域的创新和投资，促进市场成长并提高患者护理标准。

例如，2024 年 6 月，DAE 与 IDRS Labs 合作推出了“AKTOCYTE”，这是一种针对接受放射治疗的癌症患者的营养保健品，旨在改善他们在治疗期间的生活品质。它显示了支持性护理策略的创新趋势，旨在提高患者的生活品质并更有效地应对与治疗相关的挑战。此外，此类措施强调了科研机构和产业之间加强合作，以满足肿瘤学的特定营养需求，从而有可能推动该市场的进一步成长和发展。

肿瘤营养产业根据癌症类型、产品类型、配方、给药途径、剂量类型、最终用途和地区进行划分。

由于全球食道癌发生率较高，到 2032 年，食道部分将取得显着进展。食道癌患者经常出现吞嚥困难，导致营养摄取和消化面临挑战。这需要根据他们的需求提供专门的营养支持，从而推动对肿瘤营养产品的需求。此外，医学治疗的进步以及人们对营养支持在癌症护理中重要性的认识的提高，进一步推动了食道肿瘤营养市场的成长。

到 2032 年，维生素和矿物质领域将经历显着的好转，因为这些营养素在癌症治疗期间支持免疫功能和整体健康方面发挥关键作用。患者通常需要补充剂来抵消治疗相关的副作用并支持康復。医疗保健提供者对个人化营养以及维生素和矿物质在增强治疗效果方面的功效的认识不断提高，进一步推动了市场成长。针对肿瘤患者量身定制的营养配方的持续创新凸显了该细分市场在不断发展的癌症护理领域中的关键作用。

由于人口快速成长、癌症盛行率上升以及医疗保健支出不断增加，亚太地区肿瘤营养产业份额在 2024 年和 2032 年将录得显着的复合年增长率。此外，该地区不断壮大的中产阶级和不断改善的医疗基础设施正在推动癌症患者对专门营养产品的需求。本地和国际参与者对研发的大量投资也促进了市场成长。该地区强劲的经济成长和城市化进一步使亚太地区成为肿瘤营养市场的主要贡献者。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

  • 产业生态系统分析
  • 产业影响力
    • 成长动力
      • 癌症发生率上升
      • 人们越来越认识到营养在癌症治疗中的作用
      • 老年人口不断增加
    • 产业陷阱与挑战
      • 专门的肿瘤营养产品成本高
      • 监管挑战
  • 成长潜力分析
  • 波特的分析
  • PESTEL分析

第 4 章：竞争格局

  • 介绍
  • 公司矩阵分析
  • 公司定位矩阵
  • 战略仪錶板

第 5 章：市场估计与预测：按癌症类型，2021 - 2032 年

  • 主要趋势
  • 头颈癌
  • 胃肠癌和胃肠道癌症
  • 食道癌
  • 肝癌
  • 乳癌
  • 胰腺癌
  • 肺癌
  • 其他癌症类型

第 6 章：市场估计与预测：按产品类型，2021 - 2032 年

  • 主要趋势
  • 维生素和矿物质
  • 蛋白质
  • 抗氧化剂
  • 其他产品类型

第 7 章：市场估计与预测：按配方划分，2021 - 2032 年

  • 主要趋势
  • 标准
  • 元素

第 8 章：市场估计与预测：按管理途径，2021 年至 2032 年

  • 主要趋势
  • 口服
  • 注射用

第 9 章：市场估计与预测：按剂量类型，2021 - 2032

  • 主要趋势
  • 液体
  • 粉末
  • 其他剂量类型

第 10 章：市场估计与预测：按最终用途，2021 - 2032 年

  • 主要趋势
  • 医院
  • 诊所
  • 居家护理
  • 其他最终用户

第 11 章：市场估计与预测：按地区划分，2021-2032 年

  • 主要趋势
  • 北美洲
    • 我们
    • 加拿大
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 欧洲其他地区
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 亚太地区其他地区
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地区
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 中东和非洲其他地区

第 12 章：公司简介

  • Abbott Laboratories
  • Baxter International Inc.
  • B. Braun Melsungen AG
  • Danone (Nutricia)
  • Fresenius SE & Co. KGaA
  • Grifol S.A.
  • Hormel Foods Corporation
  • Meiji Holdings Co., Ltd.
  • Medtrition Inc.
  • Nestle S.A.
  • Victus, Inc.
简介目录
Product Code: 9015

Oncology Nutrition Market size will reach an 8.1% CAGR from 2024 to 2032, fueled by the increasing awareness of nutrition's crucial role in cancer treatment, coupled with advancements in medical research. As healthcare providers and patients recognize the benefits of tailored nutritional support in managing treatment side effects and improving outcomes, demand for specialized oncology nutrition products is rising. Ongoing research continues to refine nutritional strategies, highlighting their impact on patient recovery and quality of life. These factors collectively drive innovation and investment in the field, fostering market growth and improving patient care standards.

For instance, in June 2024, DAE, in partnership with IDRS Labs, introduced 'AKTOCYTE,' a nutraceutical for cancer patients undergoing radiotherapy aimed at improving their quality of life during treatment. It indicates a trend towards innovation in supportive care strategies aimed at enhancing patients' quality of life and managing treatment-related challenges more effectively. Moreover, such initiatives underscore increasing collaboration between scientific institutions and industry to address specific nutritional needs in oncology, potentially driving further growth and development in this market.

The oncology nutrition industry is divided based on cancer type, product type, formulation, route of administration, dosage type, end-use, and region.

The esophageal segment will garner noteworthy gains through 2032, owing to the high incidence of esophageal cancer worldwide. Patients with esophageal cancer often experience difficulties in swallowing, leading to challenges in nutrient intake and digestion. This necessitates specialized nutritional support tailored to their needs, driving the demand for oncology nutrition products. Additionally, advancements in medical treatments and increasing awareness about the importance of nutritional support in cancer care are further propelling the growth of the esophageal segment in the oncology nutrition market.

The vitamins and minerals segment will experience a significant upturn by 2032, driven by the critical role these nutrients play in supporting immune function and overall health during cancer treatment. Patients often require supplementation to counteract treatment-related side effects and support recovery. Increasing awareness among healthcare providers about personalized nutrition and the efficacy of vitamins and minerals in enhancing treatment outcomes further propels market growth. Continuous innovation in nutritional formulations tailored to oncology patients underscores the segment's pivotal role in the evolving landscape of cancer care.

Asia Pacific oncology nutrition industry share will record a notable CAGR during 2024 and 2032 due to its rapidly growing population, increasing prevalence of cancer, and rising healthcare expenditure. Additionally, the region's expanding middle class and improving healthcare infrastructure are driving demand for specialized nutritional products for cancer patients. Significant investments in research and development by local and international players are also bolstering market growth. The region's robust economic growth and urbanization further make the Asia Pacific a key contributor to the oncology nutrition market.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates & calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360-degree synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Rising incidence of cancer
      • 3.2.1.2 Growing awareness of nutrition's role in cancer care
      • 3.2.1.3 Growing geriatric population
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 High cost of specialized oncology nutrition products
      • 3.2.2.2 Regulatory challenges
  • 3.3 Growth potential analysis
  • 3.4 Porter's analysis
  • 3.5 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company matrix analysis
  • 4.3 Company positioning matrix
  • 4.4 Strategic dashboard

Chapter 5 Market Estimates and Forecast, By Cancer Type, 2021 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 Head and neck cancer
  • 5.3 Stomach and gastrointestinal cancer
  • 5.4 Esophageal cancer
  • 5.5 Liver cancer
  • 5.6 Breast cancer
  • 5.7 Pancreatic cancer
  • 5.8 Lung cancer
  • 5.9 Other cancer types

Chapter 6 Market Estimates and Forecast, By Product Type, 2021 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Vitamins and minerals
  • 6.3 Proteins
  • 6.4 Antioxidants
  • 6.5 Other product types

Chapter 7 Market Estimates and Forecast, By Formulation, 2021 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 Standard
  • 7.3 Elemental

Chapter 8 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

  • 8.1 Key trends
  • 8.2 Oral
  • 8.3 Parenteral

Chapter 9 Market Estimates and Forecast, By Dosage Type, 2021 - 2032 ($ Mn)

  • 9.1 Key trends
  • 9.2 Liquid
  • 9.3 Powder
  • 9.4 Other dosage types

Chapter 10 Market Estimates and Forecast, By End-use, 2021 - 2032 ($ Mn)

  • 10.1 Key trends
  • 10.2 Hospitals
  • 10.3 Clinics
  • 10.4 Homecare
  • 10.5 Other end-users

Chapter 11 Market Estimates and Forecast, By Region, 2021- 2032 ($ Mn)

  • 11.1 Key trends
  • 11.2 North America
    • 11.2.1 U.S.
    • 11.2.2 Canada
  • 11.3 Europe
    • 11.3.1 Germany
    • 11.3.2 UK
    • 11.3.3 France
    • 11.3.4 Spain
    • 11.3.5 Italy
    • 11.3.6 Rest of Europe
  • 11.4 Asia Pacific
    • 11.4.1 Japan
    • 11.4.2 China
    • 11.4.3 India
    • 11.4.4 Australia
    • 11.4.5 Rest of Asia Pacific
  • 11.5 Latin America
    • 11.5.1 Brazil
    • 11.5.2 Mexico
    • 11.5.3 Rest of Latin America
  • 11.6 Middle East and Africa
    • 11.6.1 South Africa
    • 11.6.2 Saudi Arabia
    • 11.6.3 Rest of Middle East and Africa

Chapter 12 Company Profiles

  • 12.1 Abbott Laboratories
  • 12.2 Baxter International Inc.
  • 12.3 B. Braun Melsungen AG
  • 12.4 Danone (Nutricia)
  • 12.5 Fresenius SE & Co. KGaA
  • 12.6 Grifol S.A.
  • 12.7 Hormel Foods Corporation
  • 12.8 Meiji Holdings Co., Ltd.
  • 12.9 Medtrition Inc.
  • 12.10 Nestle S.A.
  • 12.11 Victus, Inc.